Novel Sensor Identifies Bleeding Risk Profile
By HospiMedica International staff writers Posted on 10 Mar 2020 |
Image: The ClotChip device measures blood coaguability (Photo courtesy of Case Western University)
A novel miniaturized sensor can assess the clotting ability of a person’s blood 95 times faster than current methods.
The XaTek (Cleveland, OH, USA) ClotChip device is a handheld system that measures a patient's bleeding risk profile at the point of care (POC) from a single drop of blood, and is sensitive to the entire hemostatic process, including platelet disorders. The primary market of the device, which has received FDA breakthrough device designation, are users of target specific oral anticoagulants (TSOACs), which work by blocking thrombin directly or by blocking factor Xa within the coagulation cascade, as well as people suffering from the congenital bleeding disorder Hemophilia (both A and B).
The technology behind the microsensor is based on dielectric spectroscopy, which applies an external electric field to the drop of blood, and then quantitatively measures the impedance within the biologic fluid. The measurements produced directly correlate to the coaguability of the blood clot, which can then be translated into a recognizable measured scale. ClotChip, which is enabled for both WiFi and Bluetooth wireless communication, can also upload the data to the electronic medical record (EMR). The original technology was developed at Case Western Reserve University (Cleveland, OH, USA).
“Once commercially available, this device will fulfill a critical and unmet clinical need for the newer generation of drug therapies known as direct oral anti-coagulants, for which there is no point-of-care test available today,” said John Zak, co-founder and CEO of XaTek. “We intend to pursue additional indications for use in the near future, potentially including patients on other anti-coagulant therapies, those with hemophilia and other rare bleeding conditions, and those with trauma-related indications.”
Hemophilia, which is found almost only in men, is caused by a defect in the F8 or F9 gene. The most common type is hemophilia A, due to a lack of clotting factor VIII. Hemophilia B, which is less common, is caused by a lack in factor IX. Hemophilia is currently treated with infusions of the missing factors to prevent or stop debilitating bleeds, but treatment is expensive and scarce in many countries. Lack of treatment leads to chronic, disabling joint disease, while bleeding into organs and brain hemorrhages can lead to disability and death.
Related Links:
XaTek
The XaTek (Cleveland, OH, USA) ClotChip device is a handheld system that measures a patient's bleeding risk profile at the point of care (POC) from a single drop of blood, and is sensitive to the entire hemostatic process, including platelet disorders. The primary market of the device, which has received FDA breakthrough device designation, are users of target specific oral anticoagulants (TSOACs), which work by blocking thrombin directly or by blocking factor Xa within the coagulation cascade, as well as people suffering from the congenital bleeding disorder Hemophilia (both A and B).
The technology behind the microsensor is based on dielectric spectroscopy, which applies an external electric field to the drop of blood, and then quantitatively measures the impedance within the biologic fluid. The measurements produced directly correlate to the coaguability of the blood clot, which can then be translated into a recognizable measured scale. ClotChip, which is enabled for both WiFi and Bluetooth wireless communication, can also upload the data to the electronic medical record (EMR). The original technology was developed at Case Western Reserve University (Cleveland, OH, USA).
“Once commercially available, this device will fulfill a critical and unmet clinical need for the newer generation of drug therapies known as direct oral anti-coagulants, for which there is no point-of-care test available today,” said John Zak, co-founder and CEO of XaTek. “We intend to pursue additional indications for use in the near future, potentially including patients on other anti-coagulant therapies, those with hemophilia and other rare bleeding conditions, and those with trauma-related indications.”
Hemophilia, which is found almost only in men, is caused by a defect in the F8 or F9 gene. The most common type is hemophilia A, due to a lack of clotting factor VIII. Hemophilia B, which is less common, is caused by a lack in factor IX. Hemophilia is currently treated with infusions of the missing factors to prevent or stop debilitating bleeds, but treatment is expensive and scarce in many countries. Lack of treatment leads to chronic, disabling joint disease, while bleeding into organs and brain hemorrhages can lead to disability and death.
Related Links:
XaTek
Latest Critical Care News
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease
- Revascularization Improves Quality of Life for Patients with Chronic Limb Threatening Ischemia
- AI-Driven Prediction Models Accurately Predict Critical Care Patient Deterioration
- Preventive PCI for High-Risk Coronary Plaques Reduces Cardiac Events